Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of December, 2021

 

Commission File Number: 001-37353

 

BIONDVAX PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

 

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jeusalem, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 

 

 

Attached and incorporated by reference herein are the following exhibits related to the Company's contemplated underwritten public offering of 4,144,068 American Depositary Shares (“ADSs”), each representing forty ordinary shares, including ADSs issuable upon exercise in full of the underwriters’ over-allotment option.

 

 

Exhibit Index

 

Exhibit No.		Description
1.1		Underwriting Agreement, dated December 27, 2021, between the Company and Aegis Capital Corp.
5.1		Opinion of Gross Law Firm
23.1		Consent of Gross Law Firm (included in Exhibit 5.1)

 

This report on Form 6-K shall be incorporated by reference into any Registration Statement filed by the Registrant that by its terms automatically incorporates the Company’s filings and submissions with the SEC under Sections 13(a), 13(c) or 15(d) of the Securities Exchange Act of 1934.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	BiondVax Pharmaceuticals Ltd.
Date: December 29, 2021	By:	/s/ Amir Reichman
		Amir Reichman
		Chief Executive Officer

 

 

2